Legal Commentary: FDA Approves JUUL Menthol E-Cigarettes and Releases Key Scientific Evaluation Criteria

Jul.22.2025
2Firsts received a legal commentary from lawyer Zheng Mingwei’s team, analyzing the FDA’s approval of JUUL menthol e-cigarettes. The article outlines key scientific data, regulatory standards, and industry implications.

Disclaimer:

1. This article is an expert opinion piece and has been published with the author’s authorization.

2. The views expressed herein are solely those of the expert and do not reflect the views of 2Firsts.

3. 2Firsts is sharing this article for the purpose of information dissemination and to encourage diverse perspectives. Readers are advised to exercise independent judgment when interpreting or citing the information and opinions presented herein.

 


 

FDA Approves JUUL Menthol E-Cigarettes and Releases Key Scientific Evaluation Criteria

 

 

Preface

 

On July 17, 2025, the U.S. Food and Drug Administration (FDA) granted JUUL marketing authorization, approving its e-cigarette device and 3%/5% menthol pods for legal sale in the United States. This makes JUUL, following brands like NJOY and Vuse, another mainstream closed-system e-cigarette brand to receive approval for menthol-flavored products, drawing widespread industry attention. The following content summarizes key points from the FDA’s Technical Project Lead (TPL) Review, Environmental Assessment (EA), and Finding of No Significant Impact (FONSI).

 

 

I. FDA Approval Summary

 

High-risk flavored products are unlikely to meet the public health standard required by the Tobacco Control Act unless they demonstrate sufficient benefits for adult smokers in terms of switching or harm reduction. To keep such products on the market, companies must provide robust data showing full substitution among adults or significant reductions in cigarette use; otherwise, marketing authorization can be revoked at any time.

 

According to the TPL Review, the FDA’s decision in this round was based on substantial hard data. In terms of behavioral evidence, JUUL submitted a randomized controlled trial (RCT) involving 675 participants and a two-year longitudinal cohort study of approximately 2,000 individuals. These studies showed that menthol-flavored e-cigarettes enabled 51% of adult cigarette users to achieve complete seven-day substitution, significantly outperforming JUUL’s tobacco-flavored products.

 

Nicotine pharmacokinetics data revealed that JUUL menthol pods deliver approximately 79% of the plasma nicotine exposure (AUC) of cigarettes but significantly alleviate withdrawal symptoms. From a physico-chemical and toxicological standpoint, all 20 harmful and potentially harmful constituents (HPHCs) in whole-pod aerosols were below 15% of those found in 3R4F reference cigarettes. The carcinogenic risk of menthol pods was estimated by modeling to be within 5% of 3R4F levels. Ames, micronucleus, and cytotoxicity tests all returned negative results. On the biomarker level, six weeks after switching, participants exhibited reductions of 85% in NNAL and 62% in COHb. Together, these findings support the conclusion that the menthol version offers a net benefit in terms of adult substitution or harm reduction.

 

In addition, the FDA for the first time simultaneously released the Environmental Assessment and FONSI. The EA, compiled by the FDA’s Center for Tobacco Products (CTP), analyzed the manufacturing, use, and disposal lifecycle of JUUL’s pre-filled disposable pods (menthol and Virginia tobacco, 3%/5%) and hardware. The report compared two scenarios—“approval” (granting marketing authorization) and “no action” (maintaining the status quo, denying approval)—evaluating potential impacts on air, water resources, soil and biodiversity, solid and hazardous waste, and regulatory compliance. Particular attention was given to JUUL’s production facilities in New Richmond and Hudson, Wisconsin, secondhand and thirdhand vapor emissions in U.S. markets during use, and the disposal pathways for lithium batteries and nicotine residues. The results indicated that the expected production volume would not significantly increase emissions or solid waste, nor affect protected habitats, concluding no significant adverse impacts on human or environmental health.

 

Based on the EA, the FDA’s Office of Science signed the FONSI on July 10, 2025, confirming that granting marketing orders for JUUL’s five products would not have significant environmental impacts. The finding was based on the absence of additional emissions during manufacturing, manageable use-phase risks, and waste management practices comparable to existing electronic nicotine delivery systems (ENDS), thus obviating the need for a full environmental impact statement.

 

 

II. Specific Protection Requirements for Minors

 

Youth protection measures were highlighted in the TPL Review as a core condition for risk mitigation. The FDA divided these measures into two levels:

 

Online sales must implement robust age and identity verification systems to restrict purchases by minors. This requirement has been written into the marketing authorization conditions and must be continuously enforced.

 

At the device level, access restrictions such as fingerprint or other biometric unlocking mechanisms should be incorporated to ensure minors cannot activate the devices.

 

The FDA made it clear that only “device access restrictions” hold promise for meaningfully reducing youth risk from flavored ENDS. However, JUUL’s current application did not include such features. Consequently, regulators explicitly warned in the authorization: if future monitoring shows rising use among minors or the company fails to add device access restrictions, the authorization may be reassessed.

 

It is noteworthy that throughout the TPL Review, youth risk was nearly decisive for the approval trajectory of JUUL menthol pods. Considering that nearly 90% of adult smokers established nicotine dependence before age 18, and early initiation increases the likelihood of persistent addiction, “blocking youth initiation” is viewed as the top priority for public health protection. The FDA cited data from the 2024 National Youth Tobacco Survey (NYTS), which found nearly 88% of youth e-cigarette users preferred non-tobacco flavors, with menthol/mint accounting for 15.1%. Additionally, 12.6% of youth had used JUUL products in the past 30 days, and 3.2% considered JUUL their “usual brand.” Based on these findings, regulators concluded that the appeal of flavored ENDS to youth is well-documented and significant. Only when a company provides a comprehensive set of hard data—RCTs, longitudinal cohorts, HPHC comparisons, pharmacokinetics, and biomarkers—demonstrating that adult substitution benefits far outweigh youth risks will the FDA deem a product “appropriate for the protection of public health” and approve it.

 

 

III. Implications of This Approval for the E-Cigarette Industry

 

JUUL’s approval signals that the FDA has set more specific and quantifiable compliance thresholds for flavored ENDS. Behavioral, toxicological, and clinical data must align with uniform reference values. Moreover, youth protection measures are trending from “online age gates” to a composite system of “online verification + device-level access control.” The simultaneous release of the EA and FONSI also indicates that environmental assessments are becoming part of the routine review checklist, with manufacturing emissions, lithium battery disposal, and nicotine residue management now under regulatory scrutiny.

 

More importantly, this case has provided the FDA review team with comprehensive practical experience—deepening their expertise in data evaluation and procedural control, while also making publicly available many reusable operational details. As regulatory transparency increases, any flavored ENDS seeking approval must meet equally or even more stringent evidentiary requirements on public health, youth protection, and environmental impact. Otherwise, even products that have entered the review process could be denied or revoked due to imbalanced risk-benefit assessments.

 


References:

 

1. U.S. Food and Drug Administration, Center for Tobacco Products. Technical Project Lead (TPL) Review—JUUL Device and JUUL pods Menthol 3 % / 5 % & Virginia Tobacco 3 % / 5 % [R]. Silver Spring, MD: FDA; July 2025.

 

2. U.S. Food and Drug Administration, Center for Tobacco Products. Environmental Assessment for Marketing Orders for New Electronic Nicotine Delivery System Products Marketed by JUUL Labs [R]. Silver Spring, MD: FDA; July 2025.

 

3. U.S. Food and Drug Administration, Center for Tobacco Products, Office of Science. Finding of No Significant Impact (FONSI)—JUUL Device and JUUL pods [R]. Silver Spring, MD: FDA; 10 July 2025.

 

4. Centers for Disease Control and Prevention; U.S. Food and Drug Administration. National Youth Tobacco Survey 2024: Results and Detailed Tables [EB/OL]. Atlanta; Silver Spring: CDC/FDA, 2024

 

5. United States Congress. Family Smoking Prevention and Tobacco Control Act [S]. Public Law 111-31, 22 June 2009.

 


Authors:

 

1.Zheng Mingwei – Master of International Law, Shenzhen University; Chair of Corporate Practice Committee & Equity Partner, Beijing Zhongyin (Shenzhen) Law Firm; External Mentor, University of International Business and Economics; Legal Expert for Legal Daily. Phone/WeChat: 13927417509.

 

2.Chen Xuefei – Juris Doctor (JD), City University of Hong Kong; Legal Assistant, Beijing Zhongyin (Shenzhen) Law Firm.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain's cigarette volumes declined 5.2% year over year in August 2026, according to government data cited by UBS and reported by Investing.com on October 7. British American Tobacco's volumes fell 14.5%, followed by Imperial Brands at 8.8%, Philip Morris International at 6.6% and Japan Tobacco at 4.6%. JTI was the only one of the four companies to gain cigarette market share, rising six basis points to 26.7%. In France, official customs data showed an unadjusted 3.7% decline in cigarette deliveries. Adjusting for the difference in delivery days produces a decline of approximately 8.3%, consistent with the UBS figure. The bank also estimated the earnings exposure of major tobacco companies to both markets.
Market
Oct.13
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Sweden's Supreme Administrative Court has declined to hear an appeal over age verification for tobacco and nicotine products collected from parcel lockers, leaving in place a lower-court ruling that geo-located BankID verification is insufficient to securely verify the actual recipient. Haypp Group has stopped tobacco and nicotine sales through Snusnetto and is deploying a new system across its other Swedish e-commerce sites to verify the age of the person who actually opens the locker and receives the shipment. The change comes as age verification across next-generation nicotine products expands from purchase checks into retail, delivery and, for some e-cigarettes, device access itself.
Regulations
Oct.20
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands disclosed on November 17, 2026, that its global manufacturing and organisational restructuring is expected to reduce between 4,200 and 4,600 roles by the end of 2030, equivalent to approximately 16%–18% of its workforce at the end of 2025. The first phase covers 2,100 roles with departures confirmed or subject to consultation, while a further 2,100–2,500 positions are expected to be eliminated by 2030. The company is proceeding with the closure of its Langenhagen factory in Germany, has sold its manufacturing facility in Taiwan, and has transferred selected finance, procurement and supply-chain operations in Poland to Capgemini. The restructuring programme is expected to cost approximately £740 million, with Imperial targeting at least £320 million in annual cost savings by 2030.
company
Nov.18
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22